This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Sierra Oncology Future Growth
Future criteria checks 5/6
Key information
69.5%
Earnings growth rate
65.6%
EPS growth rate
| Biotechs earnings growth | 28.6% |
| Revenue growth rate | 68.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | n/a |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2024 | 143 | -2 | N/A | N/A | 2 |
| 12/31/2023 | 17 | -97 | N/A | N/A | 2 |
| 12/31/2022 | N/A | -102 | N/A | N/A | 2 |
| 3/31/2022 | N/A | -103 | -88 | -88 | N/A |
| 12/31/2021 | N/A | -95 | -79 | -79 | N/A |
| 9/30/2021 | 0 | -87 | -77 | -76 | N/A |
| 6/30/2021 | 0 | -73 | -62 | -62 | N/A |
| 3/31/2021 | 0 | -69 | -55 | -55 | N/A |
| 12/31/2020 | 0 | -81 | -52 | -52 | N/A |
| 9/30/2020 | 0 | -110 | -52 | -52 | N/A |
| 6/30/2020 | N/A | -109 | -48 | -48 | N/A |
| 3/31/2020 | N/A | -107 | -50 | -50 | N/A |
| 12/31/2019 | N/A | -88 | -51 | -51 | N/A |
| 9/30/2019 | N/A | -55 | -49 | -49 | N/A |
| 6/30/2019 | N/A | -58 | -52 | -52 | N/A |
| 3/31/2019 | N/A | -55 | -48 | -48 | N/A |
| 12/31/2018 | N/A | -53 | -45 | -45 | N/A |
| 9/30/2018 | N/A | -50 | -43 | -43 | N/A |
| 6/30/2018 | N/A | -44 | -37 | -37 | N/A |
| 3/31/2018 | N/A | -42 | -37 | -37 | N/A |
| 12/31/2017 | N/A | -42 | -36 | -36 | N/A |
| 9/30/2017 | N/A | -41 | -42 | -42 | N/A |
| 6/30/2017 | N/A | -46 | -41 | -41 | N/A |
| 3/31/2017 | N/A | -48 | -43 | -43 | N/A |
| 12/31/2016 | N/A | -48 | -41 | -41 | N/A |
| 9/30/2016 | N/A | -50 | -35 | -35 | N/A |
| 6/30/2016 | N/A | -301 | -36 | -36 | N/A |
| 3/31/2016 | N/A | -445 | -33 | -33 | N/A |
| 12/31/2015 | N/A | -453 | N/A | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: SRRA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: SRRA is expected to become profitable in the next 3 years.
Revenue vs Market: SRRA's revenue (68.6% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: SRRA's revenue (68.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SRRA's Return on Equity is forecast to be high in 3 years time